Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CytoMed Therapeutics Limited - Ordinary Shares (NQ:GDTC)

0.8600 -0.0011 (-0.13%)
Streaming Delayed Price Updated: 10:33 AM EDT, Sep 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,098
Open 0.8610
Bid (Size) 0.8500 (100)
Ask (Size) 0.8600 (200)
Prev. Close 0.8611
Today's Range 0.8550 - 0.8610
52wk Range 0.6801 - 3.680
Shares Outstanding 11,540,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector
Via Get News
News headline image
CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector
Via Get News

Performance

YTD
-38.1%
-38.1%
1 Month
+7.5%
+7.5%
3 Month
-25.2%
-25.2%
6 Month
-18.9%
-18.9%
1 Year
-53.0%
-53.0%

More News

Read More
News headline image
CytoMed, a Singapore Biotech, Revolutionizes Cancer Treatment Using Donor Immune Cells
Via Get News
News headline image
CytoMed Therapeutics Ltd – A Rising Star in Singapore’s Cancer Biotechnology Sector
Via Get News
Unusual volume stocks in Thursday's session ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Why Did CytoMed Therapeutics Stock Jump 19% Today? ↗
Via Stocktwits
News headline image
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire

Frequently Asked Questions

Is CytoMed Therapeutics Limited - Ordinary Shares publicly traded?
Yes, CytoMed Therapeutics Limited - Ordinary Shares is publicly traded.
What exchange does CytoMed Therapeutics Limited - Ordinary Shares trade on?
CytoMed Therapeutics Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares?
The ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares is GDTC on the Nasdaq Stock Market
What is the current price of CytoMed Therapeutics Limited - Ordinary Shares?
The current price of CytoMed Therapeutics Limited - Ordinary Shares is 0.8600
When was CytoMed Therapeutics Limited - Ordinary Shares last traded?
The last trade of CytoMed Therapeutics Limited - Ordinary Shares was at 09/08/26 10:33 AM ET
What is the market capitalization of CytoMed Therapeutics Limited - Ordinary Shares?
The market capitalization of CytoMed Therapeutics Limited - Ordinary Shares is 9.92M
How many shares of CytoMed Therapeutics Limited - Ordinary Shares are outstanding?
CytoMed Therapeutics Limited - Ordinary Shares has 10M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.